The FUTURE study (International Standard Randomised Controlled Trial Number ISRCTN63268739) has reignited debate on the utility of urodynamics, this time in women presenting with refractory overactive bladder (OAB) symptoms 1. The study concluded that incorporating urodynamics into the diagnostic work-up does not enhance clinical outcomes. This conclusion has sparked significant criticism and controversy within the urological community, underscoring the need for critical evaluation of the pathophysiology and management of OAB in women, clinical utility of urodynamics, and the generalisability of the FUTURE study's findings 2, 3. Over the past three decades, OAB treatment options have expanded dramatically, culminating in a strict stepwise management algorithm. However, this approach has not proved to be patient centred. Many patients find the process protracted and demotivating. Moreover, the prevailing philosophy of transitioning from least invasive to most invasive treatments may be flawed. Concerns about the long-term cognitive effects of anticholinergics raise questions about their safety compared to more invasive options, such as intradetrusor injections of botulinum toxin A or sacral neuromodulation, and the alternative pharmacotherapy, beta-3 agonists, has notably poor adherence rates. Recent updates to the AUA/Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) guidelines (https://www.auanet.org/guidelines-and-quality/guidelines/idiopathic-overactive-bladder) recommend moving away from step therapy in favour of shared decision-making and personalised treatment. Implicit in this shift toward patient-centred care in OAB management is the expectation that both clinicians and patients are equipped with adequate information to choose a treatment that maximises the likelihood of success while minimising the risk of complications. Urodynamics has long been recognised as the ‘gold standard’ for objectively diagnosing lower urinary tract (LUT) dysfunction. Furthermore, women with similar OAB symptoms can exhibit vastly different underlying dysfunctions, highlighting the necessity of urodynamics for guiding treatment decisions. One study identified BOO in 19% of women with OAB 4, for whom empirical treatments like anticholinergics or botulinum toxin would have adverse effects. Detrusor overactivity (DO) is commonly presumed to be the cause of OAB symptoms, and some argue that its presence is predictable. However, standard urodynamics demonstrates DO in only about 40–60% of patients with OAB 5. This may be because the DO is latent (in which case ambulatory urodynamics is indicated) or DO is not the primary cause of the OAB symptoms. Again, this insight is key in determining the likely benefit of treatment options. Urodynamic parameters have not only been demonstrated to predict outcomes but also to guide choice of second-line interventions by matching their primary mechanism of action to the specific LUT dysfunction demonstrated. An under-recognised but invaluable role of urodynamic testing is its ability to support shared decision-making. By increasing diagnostic certainty and revealing underlying LUT physiology, urodynamics empowers clinicians to explain clearly why specific treatments may or may not be effective and to estimate the likelihood of benefit or adverse effects. Integrating this physiological evidence with patient preferences, symptom burden, and risk tolerance enables more informed, transparent, pragmatic and personalised treatment decisions. The FUTURE study 1 has prompted essential discussions about the role of urodynamics in the management of female OAB. The value of urodynamics in characterising LUT function to allow tailored management is undeniable. As the provision of urodynamics is often limited, the motivation to prioritise which patients would benefit the most from the test is understandable. However, limited access or funding should not be reasons to downplay its overt clinical utility, which translates into five meaningful benefits for healthcare practice and the lives of our patients (Fig. 1). As the field of urology continues to evolve, it is crucial to challenge the perception that randomised controlled trials, which assess the value of a diagnostic test with the outcomes of an intervention at a population level, represent the apex of evidence, particularly in the context of heterogeneous syndromes like OAB. A nuanced understanding of each patient's unique presentation will ultimately lead to more effective and personalised treatment strategies and fully informed shared decision-making. No conflicts exist.
Solomon et al. (Wed,) studied this question.